Stay updated on Pembrolizumab Maintenance in sNSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Maintenance in sNSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Maintenance in sNSCLC Clinical Trial page
- Check5 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4 without changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedFooter updates display Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure link along with Revision: v3.3.2, a non-significant change; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page.SummaryDifference0.1%

- Check62 days agoChange DetectedA notice regarding potential delays and outdated information due to a lapse in government funding has been removed.SummaryDifference0.4%

- Check77 days agoChange DetectedBoth screenshots depict the same ClinicalTrials.gov record for NCT02564380, with no changes to core information like title, sponsor, location, eligibility criteria, or outcomes; any differences are limited to layout/visual formatting. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check105 days agoChange DetectedMajor update: page now includes a funding-related operating status notice and announces version 3.2.0, replacing v3.1.0.SummaryDifference3%

Stay in the know with updates to Pembrolizumab Maintenance in sNSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in sNSCLC Clinical Trial page.